Human pancreas protein 2 (PAN2) has a retinal reductase activity and is ubiquitously expressed in human tissues  by Belyaeva, Olga V & Kedishvili, Natalia Y
Human pancreas protein 2 (PAN2) has a retinal reductase activity and is
ubiquitously expressed in human tissues
Olga V. Belyaeva, Natalia Y. Kedishvili
Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri-Kansas City, 5007 Rockhill Road, 103 BSB,
Kansas City, MO 64110, USA
Received 26 August 2002; revised 10 October 2002; accepted 11 October 2002
First published online 22 October 2002
Edited by Hans Eklund
Abstract Human gene for pancreas protein 2 (PAN2) is a
novel member of the short-chain dehydrogenase/reductase gene
superfamily. The properties of PAN2 protein have not yet been
characterized. We present the ¢rst evidence that human PAN2
is a ubiquitously expressed microsomal enzyme that recognizes
retinoids but not steroids as substrates with the apparent Km
values between 0.08 WM and 0.4 WM. PAN2 is V4-fold more
e⁄cient in the reductive than in the oxidative direction. The
apparent Km values for NADP
+ and NADPH are 0.65 WM
and 0.32 WM versus 1200 WM and 1060 WM for NAD+ and
NADH, respectively. Kinetic constants and expression pattern
of PAN2 suggest that it is likely to function as a reductase in
vivo and might contribute to the reduction of retinaldehyde to
retinol in most human tissues.
4 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Short-chain dehydrogenases/reductases (SDRs) are a rap-
idly growing family of proteins, which includes steroid, reti-
noid, and prostaglandin dehydrogenases [1^3]. Similar to
many other SDR proteins, pancreas protein 2 (PAN2) (Gen-
Bank accession number AF237952) was initially identi¢ed as a
member of the SDR superfamily based on the presence of
signature SDR motifs in its primary structure: the cofactor
binding domain GxxxGxG at Gly-50 and the putative active
site consensus sequence YxxxK at Tyr-217. To our knowl-
edge, the substrate and cofactor speci¢city of PAN2 has not
yet been reported and its physiological function is not known.
PAN2 sharesV40% sequence identity with the recently char-
acterized all-trans-retinal reductase type 1 (RalR1), which is
highly expressed in prostate [4,5] (Fig. 1). RalR1 prefers all-
trans isomers over cis isomers of retinoids and is 50-fold more
e⁄cient in the reductive direction, suggesting that it might
contribute to the conversion of all-trans-retinaldehyde to all-
trans-retinol in prostate epithelium [4]. Retinaldehyde can be
formed in the prostate epithelium by a symmetrical cleavage
of L-carotene catalyzed by the recently cloned L-carotene
15,15P-monooxygenase [6^11]. Besides prostate, L-carotene
monooxygenase is expressed in many other tissues [6^11], sug-
gesting that various types of cells can supplement their local
retinoid stores by converting L-carotene into retinol via reti-
naldehyde as an intermediate product. While RalR1 could
reduce retinal to retinol in prostate, di¡erent enzymes could
contribute to the reduction of retinal in other tissues. In the
present study, we investigated the tissue distribution of PAN2
and determined whether it is active toward retinoids.
2. Materials and methods
2.1. Northern blot analysis
The IMAGE consortium clone #4053893 that contained the full-
length cDNA for PAN2 was obtained from Research Genetics
(Huntsville, AL, USA). The cDNA probe for Northern blot analysis
was prepared by digestion of the cDNA clone with EcoRI and XhoI
restriction endonucleases, followed by gel puri¢cation of theV1.1-kb
pair DNA fragment. Human 12-lane multiple tissue mRNA blots
(Clontech, Palo Alto, CA, USA) were hybridized with 32P-labeled
cDNA probe in ExpressHyb hybridization solution (Clontech), ac-
cording to the manufacturer’s instructions. Brie£y, the blots were pre-
hybridized in ExpressHyb solution for 30 min at 68‡C and transferred
to a fresh solution containing 2U106 cpm/ml denatured radiolabeled
cDNA. The hybridization was carried out at 68‡C for 1 h. The blots
were rinsed in 2USSC (2USSC=0.3 M NaCl, 0.03 M trisodium cit-
rate), 0.05% sodium dodecyl sulfate (SDS) several times at room tem-
perature and washed in 0.1USSC, 0.1% SDS for 10 min at 50‡C. The
mRNA bands were visualized by exposure to X-ray ¢lm at 70‡C with
two intensifying screens for 3 days.
2.2. Expression in Sf9 cells
To express PAN2 cDNA in insect cells, the cDNA clone #4053893
was digested with EcoRI and PstI restriction endonucleases. The
1327-bp fragment was gel puri¢ed and ligated into the corresponding
sites of pVL1393 baculovirus transfer vector. The construct was veri-
¢ed by DNA sequencing. Cotransfection of Sf9 cells with the transfer
vector and linearized BaculoGold DNA was performed according to
the manufacturer’s protocol (Pharmingen, San Diego, CA, USA). The
recombinant virus was ampli¢ed and used to produce PAN2 protein
essentially as described for human retinol dehydrogenase 4 (RoDH-4)
[12]. After 3 days of incubation at 27‡C, the infected cells were col-
lected by centrifugation and homogenized using French press. The
unbroken cells, cellular debris, and nuclei were removed by centrifu-
gation at 1000Ug for 10 min. Mitochondria were pelleted by centri-
fugation at 10 000Ug for 30 min, and microsomal fraction was iso-
lated by centrifugation at 105 000Ug for 1 h through a 0.6 M sucrose
cushion. Microsomes were resuspended in 0.1 M potassium phos-
phate, pH 7.4, 0.1 mM ethylenediamine tetraacetic acid (EDTA),
1 mM dithiothreitol, 20% glycerol, aliquoted and stored frozen at
370‡C. Protein concentration was determined by Lowry et al. [13]
using bovine serum albumin as a standard.
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2.3. Analysis of enzymatic activity
Catalytic activity of PAN2 was assayed in 90 mM potassium phos-
phate, pH 7.4, and 40 mM KCl at 37‡C (reaction bu¡er) in siliconized
glass tubes [4]. The oxidative and reductive activity of PAN2 toward
retinoid substrates was analyzed using all-trans and cis isomers of
retinoids (Sigma-Aldrich). The stock solutions of retinoid substrates
were prepared in ethanol and their concentrations were determined
based on the corresponding extinction coe⁄cients at the appropriate
wavelengths [14]. Ethanol-dissolved retinoids were solubilized in the
reaction bu¡er by a 10-min sonication in the presence of equimolar
delipidated bovine serum albumin. The concentration of ethanol in
the reaction mixture did not exceed 1%. The 500-Wl reactions were
started by the addition of cofactor and carried out for 10^30 min at
37‡C as described before [4], except retinaldehyde produced in the
oxidative reactions was converted into retinal oximes by the addition
of 20 Wl of 2 M hydroxylamine (pH 6.3) [15]. The amount of protein
in the reaction mixture varied from 0.02 to 250 Wg. Reaction products
were extracted twice using 2 ml of hexane [15]. Hexane was evapo-
rated under nitrogen £ow and retinoids were dissolved in 200 Wl of
high-pressure liquid chromatography (HPLC) mobile phase (hexa-
ne:acetone, 90:10). Samples were analyzed at 350 nm using 2487
Dual Absorbance Detector integrated into Waters Alliance HPLC
System. The stationary phase was Waters Spherisorb S3W column
(4.6 mmU100 mm). The £ow rate was 1 ml/min. Under these con-
ditions, all-trans-retinaldehyde and all-trans-retinol eluted at 2.09 and
4.095 min, respectively. The peak detection limits wereV1.0 pmol for
all-trans-retinal andV2.5 pmol for all-trans-retinol. The elution times
for 9-cis-retinol and 9-cis-retinaldehyde were 3.96 and 1.94 min, re-
spectively. Retinoids were quantitated by comparing their peak areas
to a calibration curve constructed from peak areas of a series of
standards.
PAN2 activity toward steroid substrates was assayed using 3H-la-
beled 5K-androstan-3K-ol-17-one (androsterone), 5-androsten-3L-ol-
17-one (dehydroepiandrosterone), 4-pregnen-3,20-dione (progester-
one), 4-pregnen-11L,21-diol-3,20-dione (corticosterone), 5K-pregnan-
3K-ol-20-one (allopregnanolone) and 14C-labeled dihydrotestosterone
(5K-androstan-17L-ol-3-one) (NEN Life Science Products, Boston,
MA, USA). Aqueous solutions of steroids were prepared as described
previously [12]. Reactions were carried out for 1 h at 37‡C in 150 Wl of
reaction bu¡er in the presence of 1 mM NADPH and 5 WM steroid
compound. The amount of the microsomal protein in the reaction
mixture was 5 Wg. Reaction products were extracted and analyzed
by thin-layer chromatography (TLC) [12]. To visualize tritiated ste-
roids, TLC plates were exposed to tritium phosphorimager screens.
14C-labeled steroids were detected by exposure to an X-ray ¢lm.
2.4. Determination of kinetic constants
Steady-state kinetic analysis was performed in the reaction bu¡er
under linear conditions with time and protein. In the reductive direc-
tion, the reaction rate was linear with up to 1.28 Wg of microsomes per
500 Wl volume for 15 min. In the oxidative direction, the rate was
linear with up to at least 0.5 Wg of microsomes per 500 Wl volume for
10 min. Kinetic constants were determined using 0.02 and 0.1 Wg of
protein in the reductive and oxidative direction, respectively. The
amount of product did not exceed 10% of the initial substrate
amount. The background value without cofactor was determined for
each concentration of substrate and was subtracted from each data
point. The experimental values were at least 4-fold higher than the
background and were expressed as meansSS.D.
The apparent Km values for the oxidation and reduction of reti-
noids were determined at ¢xed NADPþ (1.0 mM) or NADPH (1.0
mM) concentrations. Each Km determination was repeated at least
three times using six to 10 concentrations of all-trans-retinal (0.05^
5.0 WM) and all-trans-retinol (0.1^3.2 WM). The values of initial ve-
locities (nmol/min of product formed per mg of protein) were ob-
tained by non-linear regression analysis. The apparent Km values
for cofactors were determined at a ¢xed saturating concentration of
all-trans-retinal or all-trans-retinol with seven concentrations of each
cofactor: NADPH (0.05^6.4 WM), NADH (0.1^6.4 mM), NADPþ
(0.064 WM^1.0 mM) and NADþ (0.1^6.4 mM).
3. Results
3.1. Tissue distribution of PAN2 mRNA
Tissue distribution of PAN2 was analyzed by Northern
blotting using PAN2 cDNA as a probe. The cDNA was hy-
bridized to the poly(A)þ mRNA samples from 23 di¡erent
human tissues (brain was represented twice). A single major
band of approximately 1.5 kb was detected in each mRNA
sample (Fig. 2). The intensity of the band was especially
strong in the heart and skeletal muscle, followed by adrenal,
thyroid, kidney, brain, liver, trachea, stomach, prostate, spinal
cord, placenta, etc. Thus, PAN2 mRNA was present at sig-
ni¢cant levels in a wide variety of human tissues.
3.2. Characterization of PAN2 protein
To determine whether PAN2 mRNA encoded a functional
enzyme, we expressed the corresponding cDNA in insect Sf9
cells using the BaculoGold baculovirus system. The recombi-
nant protein was detected in the microsomal fraction of Sf9
cells (Fig. 3). SDS^polyacrylamide gel electrophoresis (PAGE)
analysis revealed a clearly visible protein band of V37 kDa,
which was not present in the control microsomes from the
cells infected with wild-type virus. The size of this protein
agreed with the predicted subunit molecular mass of PAN2
protein (36 864 Da).
To test whether the recombinant protein was active toward
retinoids, we assayed the retinal reductase activity of Sf9 cells
infected with the recombinant virus versus control cells using
5 WM all-trans-retinaldehyde as substrate and 1 mM NADPH
as cofactor. The assays showed that only the cells infected
with PAN2 virus exhibited a reductive activity toward retinal-
dehyde. Furthermore, distribution of the retinal reductase ac-
Table 1
Kinetic constants of PAN2 for retinoid substrates and cofactors
Substrate/cofactor Km (WM) Vmax (nmol/minUmg microsomes)
All-trans-retinal 0.08S0.02 27S1
All-trans-retinol 0.4 S 0.07 31S2
NADPH 0.32S0.04 ^
NADPþ 0.65S0.11 ^
NADH 1060S 70 ^
NADþ 1200S 120 ^
Kinetic constants were measured as described in Sections 2 and 3.
hPAN2     MAVATAAAVL AALGGALWLA ARRFVGPRVQ RLRRGGDPGL MHGKTVLITG   50
hRalR1    MVELMFPLLL LLLPFLLYMA APQIR--KML SSGVCTSTVQ LPGKVVVVTG   48
          *        *   *   *  * *                       ** *  **
hPAN2     ANSGLGRATA AELLRLGARV IMGCRDRARA EEAAGQLRRE LRQAAECGPE  100
hRalR1    ANTGIGKETA KELAQRGARV YLACRDVEKG ELVAKEIQ-- ----------   86
          ** * *  **  **   ****    ***     *  *                 
hPAN2     PGVSGVGELI VRELDLASLR SVRAFCQEML QEEPRLDVLI NNAGIFQCPY  150
hRalR1    -TTTGNQQVL VRKLDLSDTK SIRAFAKGFL AEEKHLHVLI NNAGVMMCPY  135
              *      ** ***     * ***    *  **  * *** ****   ***
hPAN2     MKTEDGFEMQ FGVNHLGHFL LTNLLLGLLK SSAPSRIVVV SSKLYKYGDI  200
hRalR1    SKTADGFEMH IGVNHLGHFL LTHLLLEKLK ESAPSRIVNV SSLAHHLGRI  185
           ** *****   ********* ** ***  **  ******* * **     * *
hPAN2     NFDDLNSEQS YNKSFCYSRS KLANILFTRE LARRLEGTNV TVNVLHPGIV  250
hRalR1    HFHNLQGEKF YNAGLAYCHS KLANILFTQE LARRLKGSGV TTYSVHPGTV  235
           *  *  *   **    *  * ******** * ***** *  * *    *** *
hPAN2     RTNLGRHIHI PLLVKPLFNL VSWAFFKTPV EGAQTSIYLA SSPEVEGVSG  300
hRalR1    QSELVRHSSF MRWMWWLFS- ---FFIKTPQ QGAQTSLHCA LTEGLEILSG  281
             * **          **       * ***   *****   *      *  **
hPAN2     RYFGDCKEEE LLPKAMDESV ARKLWDISEV MVGLLK- 336  
hRalR1    NHFSDCHVAW VSVQARNETI ARRLWDVSCD LLGLPID 318  
            * **         *  *   ** *** *     **      
Fig. 1. Alignment of protein sequences of human PAN2 (hPAN2)
and human RalR1 (hRalR1). Identical residues are indicated by a
star symbol. The cofactor binding motif and the active site consen-
sus sequence are underlined. Numbers on the right indicate the posi-
tions of the amino acid residues.
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tivity among the subcellular fractions of Sf9 cells agreed well
with the distribution of PAN2 protein. About 90% of the total
activity was recovered in the microsomal fraction. The control
microsomes did not have signi¢cant retinal reductase activity.
3.3. Analysis of PAN2 substrate and cofactor speci¢city
To establish whether PAN2 preferred all-trans or cis iso-
mers of retinoids, we compared PAN2 activity toward all-
trans-retinal and 9-cis-retinal in the presence of 1 mM
NADPH as cofactor. At 0.02 Wg of microsomes per reaction
and two di¡erent concentrations of substrate (0.1 and 1 WM),
PAN2 activity toward all-trans-retinal was consistentlyV2.5-
fold higher than toward 9-cis-retinal, suggesting that all-trans-
retinal was the preferred substrate. PAN2 activity in the oxi-
dative direction was characterized using all-trans-retinol in the
presence of 1 mM NADPþ. The apparent Km value of PAN2
for all-trans-retinol wasV5-fold higher than the apparent Km
value for all-trans-retinal (Table 1). The Vmax values in the
oxidative and reductive directions were approximately similar.
The resulting Vmax/Km value of PAN2 for oxidation of all-
trans-retinol, 78 (nmol/minUmg)/WM was 4-fold lower than
that for the reduction of retinal, 338 (nmol/minUmg)/WM,
suggesting that PAN2 was less e⁄cient in the oxidative direc-
tion.
The cofactor speci¢city of PAN2 was determined using
5 WM all-trans-retinol as substrate in the oxidative direction
and 5 WM all-trans-retinal in the reductive direction. The ap-
parent Km values for NADPþ and NADPH were less than
1 WM (Table 1). In contrast, the apparent Km values for
NADþ and NADH were in the millimolar range (Table 1).
Thus, PAN2 exhibited strong preference for the phosphory-
lated nucleotide cofactors, NADPþ and NADPH.
Since a number of retinol-active SDRs recognize steroid
compounds as substrates [16], we assayed PAN2 activity to-
ward 5 WM androsterone, dehydroepiandrosterone, progester-
one, corticosterone, allopregnanolone, and dihydrotestoster-
one. The reactions were incubated for 1 h at 37‡C in the
presence of 33.3 Wg/ml of microsomal protein. No additional
spots besides those corresponding to the substrates were de-
tected in the reactions with androsterone, dehydroepiandros-
terone, progesterone, corticosterone, or allopregnanolone. A
weak spot corresponding to 5K-androstan-3K,17L-diol was de-
tected in the reaction with dihydrotestosterone (reduction of
3-ketone group) in the presence but not in the absence of
cofactor. The estimated rate of this reaction was 0.036
nmol/minUmg microsomes, V750-fold lower than the rate
of all-trans-retinal reduction catalyzed by the same PAN2
microsomes. Thus, PAN2 did not exhibit signi¢cant activity
toward steroid compounds.
4. Discussion
Human PAN2 (AF237952) was originally identi¢ed at the
gene level by Brereton et al. (unpublished). The authors in-
dicated that PAN2 is a novel member of the SDR superfamily
similar to 11L-hydroxysteroid dehydrogenase type I. Whether
PAN2 is active toward 11L-hydroxysteroids was not reported.
We were interested whether PAN2 could recognize retinoids
as substrates because it shares about 40% amino acid sequence
identity with the novel prostate retinal reductase RalR1 re-
cently characterized in our laboratory [4]. Interestingly, de-
spite signi¢cant protein similarity, the genomic structure of
PAN2 is quite di¡erent from that of RalR1. PAN2 gene ap-
Fig. 2. Northern blot analysis of PAN2 expression in human tissues.
Human multiple tissue Northern blots (Clontech) containing a mini-
mum of 1 Wg of poly(A)þ RNA per lane were hybridized with hu-
man radiolabeled PAN2 cDNA at high stringency conditions. The
blots were exposed to X-ray ¢lm for 3 days, then stripped of resid-
ual radioactivity, reprobed with a L-actin cDNA, and exposed for
3 h (lower panel). Positions of size standards are indicated on the
right.
Fig. 3. SDS^PAGE analysis of PAN2 expression in Sf9 cells. 20 Wg
of microsomal protein isolated from Sf9 cells infected with either re-
combinant virus carrying PAN2 cDNA (PAN2 virus) or wild-type
virus (wt virus) were separated by SDS^PAGE and the gel was
stained by Coomassie R-250. The positions of SeeBlue Plus2 pre-
stained protein standards (Invitrogen) are indicated on the right.
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pears to consist of only two exons and is located on chromo-
some 2, whereas RalR1 gene consists of seven exons and is
present on chromosome 14. Furthermore, the protein prod-
ucts of the two genes have di¡erent lengths: PAN2 is a 336
amino acid polypeptide, whereas RalR1 is only 318 amino
acids long. A mouse ortholog of the human PAN2 has also
been identi¢ed (accession number AF303831). Mouse PAN2
shares 84% identity with the human protein and is two resi-
dues shorter (334 amino acids).
To determine whether PAN2 is active toward retinoids, we
expressed the corresponding cDNA in insect cells. Analysis of
the subcellular localization of PAN2 showed that, like RalR1,
PAN2 is a membrane-bound protein. Both SDS^PAGE and
activity assays localized PAN2 protein to the microsomal frac-
tion of Sf9 cells. The primary structure of PAN2 polypeptide
contains an N-terminal hydrophobic domain (residues 2^21)
that is long enough to serve as a transmembrane segment.
This segment could serve as an anchor for PAN2 attachment
to the membranes.
Kinetic analysis revealed that, ¢rst of all, PAN2 is active
toward retinoids. Secondly, similar to RalR1, PAN2 is more
e⁄cient in the reductive direction than in the oxidative and
prefers all-trans-retinaldehyde over 9-cis-retinaldehyde as sub-
strate. In fact, PAN2 appears to be a better all-trans-retinal-
dehyde reductase than RalR1 with the apparent Km value for
all-trans-retinal about 6-fold lower and the Vmax value about
1.5-fold higher than the corresponding values of RalR1 at
approximately similar level of protein expression in Sf9 cells.
The cofactor preference of PAN2 is consistent with its po-
tential role as a retinal reductase. Similar to RalR1, the ap-
parent Km values of PAN2 for NADPþ and NADPH are
three orders of magnitude lower than those for NADþ and
NADH. Since in the cytosol of liver and presumably other
cells NADPþ exists mainly in the reduced form [17], the co-
factor preference of PAN2 suggests that it is likely to function
predominantly in the reductive direction in vivo.
PAN2 is the fourth member of the SDR superfamily shown
to reduce all-trans-retinaldehydes to all-trans-retinol in the
presence of NADPH. Besides RalR1, two other less related
to PAN2 enzymes, retinal SDR1 (retSDR1) [18] (gene located
on chromosome 1) and photoreceptor retinol dehydrogenase
(prRDH) [19] (gene located on chromosome 19) catalyze ret-
inal reduction. Kinetic constants of retSDR1 and prRDH
have not been reported, however, it appears that the main
di¡erence between PAN2 and all previously characterized ret-
inal reductases lies in their tissue distribution pattern. RalR1
is highly expressed in human prostate [5], prRDH is restricted
to photoreceptor outer segments [19], and retSDR1 mRNA is
present in placenta, lung, liver, kidney, pancreas, and retina
but not in brain [18]. In contrast, PAN2 is surprisingly wide-
spread with its mRNA present at relatively high levels in all
23 di¡erent human tissues examined thus far. Interestingly,
neither of the currently known NADPþ-dependent SDR ret-
inal reductases is active toward steroid substrates. Speci¢city
for retinoids distinguishes these enzymes from the NADþ-de-
pendent SDR retinol dehydrogenases, which are also highly
active as 3K- or 17L-hydroxysteroid dehydrogenases [16].
The expression pattern of PAN2 is consistent with its po-
tential role in retinoid metabolism. All-trans-retinal, which is
recognized by PAN2 as substrate, is the immediate precursor
for a biologically active all-trans-retinoic acid that functions
as an activating ligand for a family of nuclear retinoic acid
receptors (RARs) [20]. All-trans-retinoic acid is produced
from all-trans-retinol in two oxidative steps: ¢rst, retinol is
oxidized to retinal by retinol dehydrogenases, and then, reti-
nal is oxidized to retinoic acid by retinal dehydrogenases [21].
The enzymatic machinery for retinoic acid biosynthesis is
present in many cell types and tissues [21]. The substrate,
all-trans-retinol, normally stored in the liver in the form of
retinyl esters, is delivered to peripheral tissues by the plasma
retinol binding protein (RBP) [22]. In addition, a number of
cell types appear to be able to supplement their retinoid stores
directly from the dietary L-carotene by converting L-carotene
into retinol via retinaldehyde as an intermediate product [23^
25]. In many tissues including intestinal tract, liver, kidney,
brain, stomach, testis, prostate, ovary, colon, and skeletal
muscle [7^11], the expression pattern of L-carotene 15,15P-
monooxygenase, the enzyme that cleaves L-carotene into
two molecules of retinal, overlaps with the expression of
PAN2, the enzyme that reduces retinal to retinol. In combi-
nation, the two enzymes provide the enzymatic pathway for
the conversion of dietary L-carotene into all-trans-retinol.
The intracellular levels of retinoic acid in tissues are tightly
controlled. Aberrations in retinoid signaling are early events
in carcinogenesis, and vitamin A de¢ciency has been associ-
ated with a higher incidence of cancer [26]. The molecular
mechanisms that control the levels of retinoic acid in tissues
during embryogenesis and in adulthood are poorly under-
stood. The reduction of retinal back to retinol by retinal re-
ductases to prevent excess of retinoic acid in tissues could
serve as a potential regulatory mechanism. In fact, a recent
study by Cerignoli et al. [27] presented the ¢rst evidence that
one of the retinal reductases, retSDR1, is retinoic acid induc-
ible and is frequently deleted in human neuroblastoma cell
lines. These observations provide further rationale for the
identi¢cation and characterization of all enzymes that could
be involved in retinoic acid homeostasis.
Acknowledgements: This work was supported by the National Insti-
tute on Alcohol Abuse and Alcoholism Grant AA12153 to N.Y.K.
References
[1] Jo«rnvall, H., Persson, B., Krook, M., Atrian, S., Gonzalez-
Duarte, R., Je¡ery, J. and Ghosh, D. (1995) Biochemistry 34,
6003^6013.
[2] Oppermann, U.C., Filling, C. and Jo«rnvall, H. (2001) Chem.
Biol. Interact. 130^132, 699^705.
[3] Kallberg, Y., Oppermann, U., Jo«rnvall, H. and Persson, B.
(2002) Protein Sci. 11, 636^641.
[4] Kedishvili, N.Y., Chumakova, O.V., Chetyrkin, S.V., Belyaeva,
O.V., Lapshina, E.A., Lin, D.W., Matsumura, M. and Nelson,
P.S. (2002) J. Biol. Chem. 277, 28909^28915.
[5] Lin, B., White, J.T., Ferguson, C., Wang, S., Vessella, R., Bum-
garner, R., True, L.D., Hood, L. and Nelson, P.S. (2001) Cancer
Res. 61, 1611^1618.
[6] von Lintig, J. and Vogt, K. (2000) J. Biol. Chem. 275, 11915^
11920.
[7] Wyss, A., Wirtz, G., Woggon, W., Brugger, R., Wyss, M., Fried-
lein, A., Bachmann, H. and Hunziker, W. (2000) Biochem. Bio-
phys. Res. Commun. 271, 334^336.
[8] Redmond, T.M., Gentleman, S., Duncan, T., Yu, S., Wiggert, B.,
Gantt, E. and Cunningham Jr., F.X. (2001) J. Biol. Chem. 276,
6560^6565.
[9] Paik, J., During, A., Harrison, E.H., Mendelsohn, C.L., Lai, K.
and Blaner, W.S. (2001) J. Biol. Chem. 276, 32160^32168.
[10] Yan, W., Jang, G.F., Haeseleer, F., Esumi, N., Chang, J., Ker-
rigan, M., Campochiaro, M., Campochiaro, P., Palczewski, K.
and Zack, D.J. (2001) Genomics 72, 193^202.
FEBS 26721 5-11-02
O.V. Belyaeva, N.Y. Kedishvili/FEBS Letters 531 (2002) 489^493492
[11] Lindqvist, A. and Andersson, S. (2002) J. Biol. Chem. 277,
23942^23948.
[12] Gough, W.H., VanOoteghem, S., Sint, T. and Kedishvili, N.Y.
(1998) J. Biol. Chem. 273, 19778^19785.
[13] Lowry, O.H., Rosebrough, N.H., Farr, A.L. and Randall, R.J.
(1951) J. Biol. Chem. 193, 265^275.
[14] Furr, H.C., Barua, A.B. and Olson, J.A. (1994) in: The Reti-
noids: Biology, Chemistry, and Medicine, 2nd edn. (Sporn,
M.B., Roberts, A.B. and Goodman, D.S., Eds.), pp. 179^209,
Raven Press, New York.
[15] Landers, G.M. (1990) in: Retinoids, Part A, Molecular and Met-
abolic Aspects (Packer, L., Ed.), Methods Enzymol. Vol. 189, pp.
70^80, Academic Press, San Diego, CA.
[16] Napoli, J.L. (2001) Mol. Cell. Endocrinol. 171, 103^109.
[17] Veech, R.L., Eggleston, L.V. and Krebs, H.A. (1969) Biochem.
J. 115, 609^619.
[18] Haeseleer, F., Huang, J., Lebioda, L., Saari, J.C. and Palczewski,
K. (1998) J. Biol. Chem. 273, 21790^21799.
[19] Rattner, A., Smallwood, P.M. and Nathans, J. (2000) J. Biol.
Chem. 275, 11034^11043.
[20] Mangelsdorf, D., Umesono, K. and Evans, R.M. (1994) in: The
Retinoids: Biology, Chemistry, and Medicine, 2nd edn. (Sporn,
M.B., Roberts, A.B. and Goodman, D.S., Eds.), pp. 179^209,
Raven Press, New York.
[21] Napoli, J.L., Posch, K.P., Fiorella, P.D. and Boerman, M.H.
(1991) Biomed. Pharmacother. 45, 131^143.
[22] Blaner, W.S. and Olson, J.A. (1994) in: The Retinoids: Biology,
Chemistry, and Medicine, 2nd edn. (Sporn, M.B., Roberts, A.B.
and Goodman, D.S., Eds.), pp. 179^209, Raven Press, New
York.
[23] During, A., Albaugh, G. and Smith, J.C. (1998) Biochem. Bio-
phys. Res. Commun. 249, 467^474.
[24] Scita, G., Aponte, G.W. and Wolf, G. (1992) J. Nutr. Biochem.
3, 118^123.
[25] Wei, R.R., Wamer, W.G., Lambert, L.A. and Kornhauser, A.
(1998) Nutr. Cancer 30, 53^58.
[26] Sun, S.Y. and Lotan, R. (2002) Crit. Rev. Oncol. Hematol. 41,
41^55.
[27] Cerignoli, F., Guo, X., Cardinali, B., Rinaldi, C., Casaletto, J.,
Frati, L., Screpanti, I., Gudas, L.J., Gulino, A., Thiele, C.J. and
Giannini, G. (2002) Cancer Res. 62, 1196^1204.
FEBS 26721 5-11-02
O.V. Belyaeva, N.Y. Kedishvili/FEBS Letters 531 (2002) 489^493 493
